| ［1］ |
Halsted WS. I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June， 1889， to January， 1894［J］. Ann Surg， 1894， 20（5）： 497-555.
|
| ［2］ |
Fisher B， Jeong JH， Anderson S， et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy， total mastectomy， and total mastectomy followed by irradiation［J］. N Engl J Med， 2002， 347（8）： 567-575.
|
| ［3］ |
Krag DN， Anderson SJ， Julian TB， et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer： overall survival findings from the NSABP B-32 randomised phase 3 trial［J］. Lancet Oncol， 2010， 11（10）： 927-933.
|
| ［4］ |
Bartels SAL， Donker M， Poncet C， et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer： 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial［J］. J Clin Oncol， 2023， 41（12）： 2159-2165.
|
| ［5］ |
de Boniface J， Appelgren M， Szulkin R， et al. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment： a post-hoc analysis of the randomised， phase 3 SENOMAC trial［J］. Lancet Oncol， 2024， 25（9）： 1222-1230.
|
| ［6］ |
Gentilini OD， Botteri E， Sangalli C， et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes： the SOUND randomized clinical trial［J］. JAMA Oncol， 2023， 9（11）： 1557-1564.
|
| ［7］ |
Reimer T， Stachs A， Veselinovic K， et al. Axillary surgery in breast cancer—primary results of the INSEMA trial［J］. N Engl J Med， 2025， 392（11）： 1051-1064.
|
| ［8］ |
de Boniface J， Filtenborg Tvedskov T， Rydén L， et al. Omitting axillary dissection in breast cancer with sentinel-node metastases［J］. N Engl J Med， 2024， 390（13）： 1163-1175.
|
| ［9］ |
Kühn T， Banys-Paluchowski M， Ditsch N， et al. More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy—primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3（R） study［J］. Clin Cancer Res， 2026， 32（4 Suppl）： GS2-01.
|
| ［10］ |
Schipper RJ， van Roozendaal LM， Wintraecken VM， et al. Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy： results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years［J］. Clin Cancer Res， 2026， 32（4 Suppl）： GS2-11.
|
| ［11］ |
Park KU， Somerfield MR， Anne N， et al. Sentinel lymph node biopsy in early-stage breast cancer： ASCO guideline update［J］. J Clin Oncol， 2025， 43（14）： 1720-1741.
|
| ［12］ |
中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范（2026年版）［J］. 中国癌症杂志，2025， 35（12）： 1157-1255.
|
| ［13］ |
Chung HL， Tso HH， Middleton LP， et al. Axillary nodal metastases in invasive lobular carcinoma versus invasive ductal carcinoma： comparison of node detection and morphology by ultrasound［J］. AJR Am J Roentgenol， 2022， 218（1）： 33-41.
|
| ［14］ |
Rastogi P， O'Shaughnessy J， Martin M， et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive， human epidermal growth factor receptor 2-negative， high-risk early breast cancer： results from a preplanned monarchE overall survival interim analysis， including 5-year efficacy outcomes［J］. J Clin Oncol， 2024， 42（9）： 987-993.
|
| ［15］ |
Hortobagyi GN， Lacko A， Sohn J， et al. A phase Ⅲ trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer： final invasive disease-free survival results from the NATALEE trial［J］. Ann Oncol， 2025， 36（2）： 149-157.
|
| ［16］ |
Huang D， Shi Y， Cao W， et al. Exempting axillary staging surgery in breast cancer using multimodal ultrasound imaging and radiomics of sentinel lymph nodes［J］. EClinicalMedicine， 2026， 92： 103782.
|
| ［17］ |
Giuliano AE， Ballman KV， McCall L， et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis： the ACOSOG Z0011 （Alliance） randomized clinical trial［J］. JAMA， 2017， 318（10）： 918-926.
|
| ［18］ |
de Boniface J， Filtenborg Tvedskov T， Rydén L， et al. Omission of completion axillary dissection in patients with breast cancer and sentinel lymph node macrometastases： overall survival and patient-reported arm morbidity from the randomized SENOMAC trial［J］. J Clin Oncol， 2026， 44（17 Suppl）： LBA503.
|
| ［19］ |
Caudle AS， Yang WT， Krishnamurthy S， et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes： implementation of targeted axillary dissection［J］. J Clin Oncol， 2016， 34（10）： 1072-1078.
|
| ［20］ |
Kühn T， Banys-Paluchowski M， Ditsch N， et al. Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer： multicentre AXSANA cohort study［J］. Br J Surg， 2025， 112（9）： znaf180.
|
| ［21］ |
Banys-Paluchowski M， Hartmann S， de Boniface J， et al. Marking techniques for target lymph nodes in node-positive breast cancer treated with neoadjuvant therapy in the AXSANA/EUBREAST-03/AGO-B-053 study［J］. J Clin Oncol， 2026， 44（7）： 575-585.
|
| ［22］ |
Montagna G， Alvarado M， Myers S， et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy （OPBC-07/microNAC）： an international， retrospective cohort study［J］. Lancet Oncol， 2026， 27（1）： 57-67.
|
| ［23］ |
Boughey JC， Yu H， Switalla K， et al. Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer： results from >1 500 patients on the I-SPY2 clinical trial［J］. Ann Surg Oncol， 2025， 32（5）： 3278-3291.
|
| ［24］ |
Di Micco R， Hartmann S， Banys-Paluchowski M， et al. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients-results from the prospective AXSANA registry trial［J］. Eur J Cancer， 2025， 226： 115607.
|